

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595971	
Filing Date		2006-05-23	
First Named Inventor	Humphrey		
Art Unit	NA		
Examiner Name	Not Assigned		
Attorney Docket Number	80-06		

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5714576		1998-02-03	Hruby et al.	
	2	5683981		1997-11-04	Hruby et al.	
	3	5674839		1997-10-07	Hruby et al.	
	4	5049547		1991-09-07	Hruby et al.	
	5	4918055		1990-04-17	Hruby et al.	
	6	4866038		1989-09-12	Hruby et al.	
	7	4485039		1989-11-27	Hruby et al.	
	8	4457864		1984-07-03	Hruby et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10595971
Filing Date	2006-05-23
First Named Inventor	Humphrey
Art Unit	NA
Examiner Name	Not Assigned
Attorney Docket Number	80-06

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	05048967	WO		2005-06-02	Humphrey		<input type="checkbox"/>
	2	03072072	WO		2003-09-04	Dorr et al.		<input type="checkbox"/>
	3	87004623	WO		1987-08-13	Hruby et al.		<input type="checkbox"/>
	4	618733	AU		1992-01-09	Hruby et al.		<input type="checkbox"/>
	5	597630	AU		1990-06-07	Hruby et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595971
Filing Date	2006-05-23
First Named Inventor	Humphrey
Art Unit	NA
Examiner Name	Not Assigned
Attorney Docket Number	80-06

1	Abdel-Malek et al. (Feb. 1995) "Mitogenic and Melanogenic Stimulation of Normal Human Melanocytes by Melanotropic Peptides," Proc. Natl. Acad. Sci. USA 92(5):1789-1793	<input type="checkbox"/>
2	Abdel-Malek et al. (Oct. 1999) "The Melanocortin-1 Receptor and Human Pigmentation," Ann. N.Y. Acad. Sci. 885:117-133	<input type="checkbox"/>
3	Abel-Malek et al. (2000) "The Melanocortin-1 Receptor is a Key Regulator of Human Cutaneous Pigmentation," Pigment Cell Res. 13(Sup. 8):156-162	<input type="checkbox"/>
4	Bastiaens et al. (2001) "Melanocortin-1 Receptor Gene Variants Determine the Risk of Nonmelanoma Skin Cancer Independently of Fair Skin and Red Hair," Am. J. Hum. Genet. 68(4):884-894	<input type="checkbox"/>
5	Box et al. (1997) "Characterization of Melanocyte Stimulating Hormone Receptor Variant Alleles in Twins with Red Hair," Hum. Mol. Genet. 6(11):1891-1897	<input type="checkbox"/>
6	De Luca et al. (1993) "Alpha Melanocyte Stimulating Hormone (Alpha MSH) Stimulates Normal Human Melanocyte Growth by Binding to High-Affinity Receptors," J. Cell. Sci. 105(4):1079-1084	<input type="checkbox"/>
7	Dorr et al. (2000) "Increased Eumelanin Expression and Tanning is Induced by a Superpotent Melanotropin [Nle4-D-Phe7]-Alpha-MSH in Humans," Photochem. Photobiol. 72(4):526-532	<input type="checkbox"/>
8	Dwyer et al. (1998) "The Use of Spectrophotometry to Estimate Melanin Density in Caucasians," Cancer Epidemiol. Biomarkers Prev. 7(3):203-206	<input type="checkbox"/>
9	Dwyer et al. (2002) "Cutaneous Melanin Density of Caucasians Measured by Spectrophotometry and Risk of Malignant Melanoma Basal Cell Carcinoma, and Squamous Cell Carcinoma of the Skin," Am. J. Epidemiol. 155 (7):614-621	<input type="checkbox"/>
10	Fitzpatrick, T.B. (1988) "The Validity and Practicality of Sun-Reactive Skin Types I Through VI," Arch. Dermatol. 124 (6):869-871	<input type="checkbox"/>
11	Frandsen et al. (1998) "Human Pigmentation Phenotype: A Point Mutation Generates Nonfunctional MSH Receptor," Biochem. Biophys. Res. Commun. 245(2):490-492	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595971
Filing Date	2006-05-23
First Named Inventor	Humphrey
Art Unit	NA
Examiner Name	Not Assigned
Attorney Docket Number	80-06

12	Healy et al. (2001) "Functional Variation of MC1R Alleles from Red-Haired Individuals," Hum. Mol. Genet. 10 (21):2397-2402	<input type="checkbox"/>
13	Hunt et al. (1994) "Alpha-Melanocyte Stimulating Hormone and Its Analogue Nle4DPhe7 Alpha-MSH Affect Morphology, Tyrosinase Activity and Melanogenesis in Cultured Human Melanocytes," J. Cell. Sci. 107(1):205-211	<input type="checkbox"/>
14	Hunt et al. (1995) "Nle4DPhe7 Alpha-Melanocyte-Stimulating Hormone Increases the Eumelanin:Phaeomelanin Ratio in Cultured Human Melanocytes," J. Invest. Dermatol. 104(1):83-85	<input type="checkbox"/>
15	Jimenez-Cervantes et al. (2001) "Thr40 and Met122 are New Partial Loss-of-Function Natural Mutations of the Human Melanocortin 1 Receptor," FEBS Lett. 508(1):44-48	<input type="checkbox"/>
16	John et al. (2002) "Four Novel Variants in MC1R in Red-Haired South African Individuals of European Descent: S83P, Y152X, A171D, P256S," Hum. Mutat. 19(4):461-462	<input type="checkbox"/>
17	Kadekaro et al. (Jun. 2003) "Significance of the Melanocortin 1 Receptor in Regulating Human Melanocyte Pigmentation, Proliferation, and Survival," Ann. N.Y. Acad. Sci. 994:359-365	<input type="checkbox"/>
18	Kennedy et al. (2001) "Melanocortin 1 Receptor (MC1R) Gene Variants are Associated with and Increased Risk for Cutaneous Melanoma Which is Largely Independent of Skin Type and Hair Color," J. Invest Dermatol. 117(2):294-300	<input type="checkbox"/>
19	Levine et al. (1991) "Induction of Skin Tanning by Subcutaneous Administration of a Potent Synthetic Melanotropin," JAMA 266(19):2730-2736	<input type="checkbox"/>
20	Menon et al. (1983) "A Comparative Study of the Physical and Chemical Properties of Melanins Isolated from Human Black and Red Hair," J. Invest. Dermatol. 80(3):202-206	<input type="checkbox"/>
21	Menon et al. (1983) "Effects of Ultraviolet-Visible Irradiation in the Presence of Melanin Isolated from Human Black or Red Hair Upon Ehrlich Ascites Carcinoma Cells," Cancer Res. 43(7):3165-3169	<input type="checkbox"/>
22	Palmer et al. (2000) "Melanocortin-1 Receptor Polymorphisms and Risk of Melanoma: Is the Association Explained Solely by Pigmentation Phenotype," Am. J. Hum. Genet. 66(1):176-186	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10595971
Filing Date		2006-05-23
First Named Inventor	Humphrey	
Art Unit	NA	
Examiner Name	Not Assigned	
Attorney Docket Number	80-06	

23	Sanchez et al. (2002) "Loss-of-Function Variants of the Human Melanocortin-1 Receptor Gene in Melanoma Cells Define Structural Determinants of Receptor Function," Eur. J. Biochem. 269(24):6133-6141	<input type="checkbox"/>
24	Sawyer et al. (Oct. 1980) "4-Norleucine, 7-D-Phenylalanine-Alpha-Melanocyte-Stimulating Hormone: A Highly Potent Alpha-Melanotropin with Ultralong Biological Activity," Proc. Natl. Acad. Sci. USA 77(10):5754-5758	<input type="checkbox"/>
25	Schloth et al. (1999) "Loss of Function Mutations of the Human Melanocortin 1 Receptor are Common and are Associated with Red Hair," Biochem. Biophys. Res. Commun. 260(2):488-491	<input type="checkbox"/>
26	Scott et al. (2002) "Human Melanocortin 1 Receptor Variants, Receptor Function and Melanocyte Response to UV Radiation," J. Cell. Sci. 115(11):2349-2355	<input type="checkbox"/>
27	Smith et al. (1998) "Melanocortin 1 Receptor Variants in an Irish Population," J. Invest. Dermatol. 111(1):119-122	<input type="checkbox"/>
28	Sturm et al. (Oct. 2002) "Skin Colour and Skin Cancer – MC1R, The Genetic Link," Melanoma Res. 12(5):406-416	<input type="checkbox"/>
29	Sturm et al. (2003) "Genetic Association and Cellular Function of MC1R Variant Alleles in Human Pigmentation," Ann. N.Y. Acad. Sci. 994:348-358	<input type="checkbox"/>
30	Valverde et al. (1996) "The Asp84Glu Variant of the Melanocortin 1 Receptor (MC1R) is Associated with Melanoma," Hum. Mol. Genet. 5(10):1663-1666	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10595971
Filing Date	2006-05-23
First Named Inventor	Humphrey
Art Unit	NA
Examiner Name	Not Assigned
Attorney Docket Number	80-06

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/ellenwinner/	Date (YYYY-MM-DD)	2006-08-29
Name/Print	Ellen P. Winner	Registration Number	28547

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.